Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Acrobiosystems Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301080 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Acrobiosystems Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrobiosystems Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrobiosystems Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Acrobiosystems Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acrobiosystems Co (SZSE:301080) has a FCF Margin % of 3.47% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Acrobiosystems Co and its competitors. According to the industry distribution chart, Acrobiosystems Co ranks #121 out of 954 companies in the Biotechnology industry, placing it in the top 12.7%.
Is Acrobiosystems Co's FCF Margin % too high?
Acrobiosystems Co's current FCF Margin % is 3.47%. Based on the distribution chart, Acrobiosystems Co ranks #121 out of 954 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acrobiosystems Co has a GF Score™ of 92/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acrobiosystems Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Acrobiosystems Co ranks #121 out of 954 companies for FCF Margin %. This places Acrobiosystems Co in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Acrobiosystems Co and its competitors. Acrobiosystems Co's current FCF Margin % is 3.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrobiosystems Co stock overvalued right now?
Based on GuruFocus' analysis, Acrobiosystems Co (SZSE:301080) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥61.37, compared to a current price of ¥88.21 — trading 43.7% above its estimated fair value. The current FCF Margin % is 3.47%. Acrobiosystems Co's overall GF Score™ is 92/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Acrobiosystems Co (SZSE:301080), the current FCF Margin % is 3.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acrobiosystems Co (SZSE:301080) Overvalued in 2026?
Based on GuruFocus' analysis, Acrobiosystems Co stock appears to be overvalued.
The current stock price of ¥88.21 is trading 43.7% above its estimated GF Value™ of ¥61.37.
GuruFocus considers Acrobiosystems Co to be Significantly Overvalued.
Key valuation signals for SZSE:301080:
FCF Margin %: 3.47%
GF Value™: ¥61.37 vs. price of ¥88.21 (43.7% above fair value)
No single metric tells the full story. See the SZSE:301080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
92GF Score
Get the complete analysis for SZSE:301080
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301080 has been successfully added to your 
